Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.43 Consensus Price Target from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have received a consensus rating of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $9.43.

Several equities research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $5.00 price target (down previously from $7.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. Royal Bank of Canada reissued an “outperform” rating and issued a $8.00 target price (down from $10.00) on shares of Pyxis Oncology in a research report on Friday, December 20th. William Blair cut Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. Finally, Stephens assumed coverage on Pyxis Oncology in a report on Friday, November 8th. They issued an “overweight” rating and a $13.00 price objective for the company.

Insider Activity at Pyxis Oncology

In other news, CFO Pamela Ann Connealy acquired 88,850 shares of Pyxis Oncology stock in a transaction that occurred on Tuesday, November 26th. The stock was bought at an average price of $1.96 per share, with a total value of $174,146.00. Following the completion of the purchase, the chief financial officer now owns 1,199,143 shares in the company, valued at approximately $2,350,320.28. The trade was a 8.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 9.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Intech Investment Management LLC purchased a new stake in shares of Pyxis Oncology in the third quarter worth $55,000. SG Americas Securities LLC bought a new position in Pyxis Oncology in the 3rd quarter worth about $58,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Pyxis Oncology in the 2nd quarter valued at about $65,000. MetLife Investment Management LLC boosted its position in shares of Pyxis Oncology by 41.1% during the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after acquiring an additional 5,484 shares during the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of Pyxis Oncology during the third quarter worth about $107,000. 39.09% of the stock is owned by institutional investors.

Pyxis Oncology Stock Performance

NASDAQ PYXS opened at $1.61 on Tuesday. The company has a market capitalization of $95.74 million, a PE ratio of -1.56 and a beta of 1.06. Pyxis Oncology has a 52-week low of $1.49 and a 52-week high of $6.85. The company has a 50-day simple moving average of $2.39 and a 200 day simple moving average of $3.10.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.